Psychopharmacology for Neurologists

ABSTRACT

Psychiatric disorders are common in neurological patients, and psychopharmacological agents are frequently used to treat agitation and other problems in neurological practice. Antidepressants are effective for depression caused by neurological illness, but they can interact with other medications. Antianxiety drugs can aggravate cognitive disorders and should be used cautiously in this context. Antipsychotic drugs can be useful for acute agitation, but they are being found to be neither effective nor safe for chronic nonpsychotic agitation. Other agents such as β blockers and serotonergic agents are being found to be more useful. Uses, doses, adverse effects, and interactions of psychiatric medications in neurology are summarized in this article, and suggestions are provided for the practical application of these treatments.

KEYWORDS

Psychopharmacology - medication - psychiatric - adverse effects - agitation - antidepressant - antipsychotic - anxiolytic

REFERENCES

• 1 Schildkraut J J, Schanberg S M, Breese G R, Kopin I J. Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action.  Am J Psychiatry. 1967;  124(5) 600-608
• 2 Gold P W, Licinio J, Wong M L, Chrousos G P. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and the mechanisms of action of antidepressant drugs.  Ann N Y Acad Sci. 1995;  771 716-729
• 3 Shelton R C. Intracellular mechanisms of antidepressant drug action.  Harv Rev Psychiatry. 2000;  8(4) 161-174
• 4 Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview.  Pharmacol Rev. 2006;  58(1) 115-134
• 5 Caley C F. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors.  Ann Pharmacother. 1997;  31(12) 1481-1489
• 6 Dubovsky S L. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents.  J Clin Psychiatry. 1994;  55(Suppl) 34-44
• 7 Gerber P E, Lynd L D. Selective serotonin-reuptake inhibitor-induced movement disorders.  Ann Pharmacother. 1998;  32(6) 692-698
• 8 Gill H S, DeVane C L, Risch S C. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses.  J Clin Psychopharmacol. 1997;  17(5) 377-389
• 9 Dubovsky S L, Thomas M. Tardive dyskinesia associated with fluoxetine.  Psychiatr Serv. 1996;  47(9) 991-993
• 10 Movig K L, Leufkens H G, Lenderink A W et al.. Association between antidepressant drug use and hyponatraemia: a case-control study.  Br J Clin Pharmacol. 2002;  53(4) 363-369
• 11 Dubovsky S L. Clinical Guide to Psychotropic Medications. New York, NY; WW Norton 2005
• 12 Mukherjee S, Sackeim H A, Schnur D B. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience.  Am J Psychiatry. 1994;  151(2) 169-176
• 13 Devanand D P, Dwork A J, Hutchinson E R, Bolwig T G, Sackeim H A. Does ECT alter brain structure?.  Am J Psychiatry. 1994;  151(7) 957-970
• 14 Gwinn R P, Kondratyev A, Gale K. Time-dependent increase in basic fibroblast growth factor protein in limbic regions following electroshock seizures.  Neuroscience. 2002;  114(2) 403-409
• 15 Taylor S M. Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive therapy.  J ECT. 2008;  24(2) 160-165
• 16 Dubovsky S L. Using electroconvulsive therapy for patients with neurological disease.  Hosp Community Psychiatry. 1986;  37(8) 819-825
• 17 Krueger R B, Fama J M, Devanand D P, Prudic J, Sackeim H A. Does ECT permanently alter seizure threshold?.  Biol Psychiatry. 1993;  33(4) 272-276
• 18 Aarsland D, Larsen J P, Waage O, Langeveld J H. Maintenance electroconvulsive therapy for Parkinson's disease.  Convuls Ther. 1997;  13(4) 274-277
• 19 Moellentine C, Rummans T A, Ahlskog J E et al.. Effectiveness of ECT in patients with parkinsonism.  J Neuropsychiatry Clin Neurosci. 1998;  10(2) 187-193
• 20 Kennedy R, Mittal D, O'Jile J. Electroconvulsive therapy in movement disorders: an update.  J Neuropsychiatry Clin Neurosci. 2003;  15(4) 407-421
• 21 Andrade C, Kurinji S. Continuation and maintenance ECT: a review of recent research.  J ECT. 2002;  18(3) 149-158
• 22 Weiner R D. American Psychiatric Association Committee on Electroconvulsive Therapy .The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. Washington, DC; American Psychiatric Association 1990
• 23 Dubovsky S L. Electroconvulsive therapy. In: Kaplan HI, Sadock BJ Comprehensive Textbook of Psychiatry/VI. 6th ed. Baltimore, MD; Williams and Wilkins 1995: 2129-2140
• 24 Dannon P N, Dolberg O T, Schreiber S, Grunhaus L. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals—preliminary report.  Biol Psychiatry. 2002;  51(8) 687-690
• 25 Grunhaus L, Schreiber S, Dolberg O T, Polak D, Dannon P N. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression.  Biol Psychiatry. 2003;  53(4) 324-331
• 26 Kozel F A, George M S. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression.  J Psychiatr Pract. 2002;  8 270-275
• 27 Furukawa T A, Streiner D L, Young L T. Antidepressant and benzodiazepine for major depression.  Cochrane Database Syst Rev. 2002;  (1) CD001026
• 28 Dubovsky S L. Agents acting on the benzodiazepine receptor. In: Sadock B, Sadock V, Ruiz P Comprehensive Textbook of Psychiatry. 9th ed. Baltimore, MD; Williams and Wilkins 2009
• 29 Busto U, Sellers E M, Naranjo C A, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines.  N Engl J Med. 1986;  315(14) 854-859
• 30 Brooks J O, Hoblyn J C. Neurocognitive costs and benefits of psychotropic medications in older adults.  J Geriatr Psychiatry Neurol. 2007;  20(4) 199-214
• 31 Smith D E, Wesson D R. Benzodiazepines and other sedative-hypnotics. In: Galanter M, Kleber HD American Psychiatric Press Textbook of Substance Abuse Treatment, 2nd ed. Washington, DC; American Psychiatric Press 1999: 239-250
• 32 Smith D E, Wesson D R. Phenobarbital technique for treatment of barbiturate dependence.  Arch Gen Psychiatry. 1971;  24(1) 56-60
• 33 Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach.  Arch Intern Med. 1999;  159(20) 2456-2460
• 34 Pande A C, Pollack M H, Crockatt J G et al.. Placebo-controlled study of gabapentin treatment of panic disorder.  J Clin Psychopharmacol. 2000;  20(4) 467-471
• 35 Pande A C, Feltner D E, Jefferson J W et al.. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.  J Clin Psychopharmacol. 2004;  24(2) 141-149
• 36 Dubovsky S L. Agents acting on the benzodiazepine receptor. In: Sadock B, Sadock V, Ruiz P Comprehensive Textbook of Psychiatry. 10th ed. Baltimore, MD; Williams and Wilkins 2009
• 37 Davis J M, Chen N, Glick I D. A meta-analysis of the efficacy of second-generation antipsychotics.  Arch Gen Psychiatry. 2003;  60(6) 553-564
• 38 Lieberman J A, Stroup T S, McEvoy J P Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med. 2005;  353(12) 1209-1223
• 39 Jones P B, Barnes T R, Davies L et al.. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).  Arch Gen Psychiatry. 2006;  63(10) 1079-1087
• 40 Marder S R, Essock S M, Miller A L et al.. The Mount Sinai conference on the pharmacotherapy of schizophrenia.  Schizophr Bull. 2002;  28(1) 5-16
• 41 Tohen M, Calabrese J R, Sachs G S et al.. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.  Am J Psychiatry. 2006;  163(2) 247-256
• 42 Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).  J Affect Disord. 2008;  109(3) 251-263
• 43 Allison D B, Mentore J L, Heo M et al.. Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156(11) 1686-1696
• 44 Gianfrancesco F D, Grogg A L, Mahmoud R A, Wang R H, Nasrallah H A. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.  J Clin Psychiatry. 2002;  63(10) 920-930
• 45 American Diabetes Association . Consensus development conference on antipsychotic drugs and obesity and diabetes.  Diabetes Care. 2004;  27(2) 596-601
• 46 Reilly J G, Ayis S A, Ferrier I N, Jones S J, Thomas S HL. Thioridazine and sudden unexplained death in psychiatric in-patients.  Br J Psychiatry. 2002;  180 515-522
• 47 Ray W A, Chung C P, Murray K T, Hall K, Stein C M. Atypical antipsychotic drugs and the risk of sudden cardiac death.  N Engl J Med. 2009;  360(3) 225-235
• 48 Shale J H, Shale C M, Mastin W D. A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients.  J Clin Psychiatry. 2003;  64(5) 500-505
• 49 Passmore M J, Gardner D M, Polak Y, Rabheru K. Alternatives to atypical antipsychotics for the management of dementia-related agitation.  Drugs Aging. 2008;  25(5) 381-398
• 50 Friedman J H. Atypical antipsychotics in the elderly with Parkinson disease and the “black box” warning.  Neurology. 2006;  67(4) 564-566
• 51 Rabins P V, Lyketsos C G. Antipsychotic drugs in dementia: what should be made of the risks?.  JAMA. 2005;  294(15) 1963-1965
• 52 Finkel S, Kozma C, Long S et al.. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.  Int Psychogeriatr. 2005;  17(4) 617-629
• 53 Kales H C, Valenstein M, Kim H M et al.. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications.  Am J Psychiatry. 2007;  164(10) 1568-1576, quiz 1623
• 54 Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric comorbidity.  Neurology. 2006;  67(12, Suppl 4) S39-S44
• 55 Kurlan R, Cummings J, Raman R, Thal L. Alzheimer's Disease Cooperative Study Group . Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.  Neurology. 2007;  68(17) 1356-1363
• 56 Chacko R C, Hurley R A, Harper R G, Jankovic J, Cardoso F. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease.  J Neuropsychiatry Clin Neurosci. 1995;  7(4) 471-475
• 57 Strawn J R, Keck Jr P EJ, Caroff S N. Neuroleptic malignant syndrome.  Am J Psychiatry. 2007;  164(6) 870-876
• 58 Panitch H S, Thisted R A, Smith R A Psuedobulbar Affect in Multiple Sclerosis Study Group et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.  Ann Neurol. 2006;  59(5) 780-787
• 59 Loj J, Solomon G D. Migraine prophylaxis: who, why, and how.  Cleve Clin J Med. 2006;  73(9) 793-794, 797, 800–801 passim
• 60 Saarto T, Wiffen P J. Antidepressants for neuropathic pain.  Cochrane Database Syst Rev. 2007;  (4) CD005454
• 61 Battaglia J, Lindborg S R, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients.  Am J Emerg Med. 2003;  21(3) 192-198
• 62 Battaglia J, Moss S, Rush J et al.. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study.  Am J Emerg Med. 1997;  15(4) 335-340
• 63 Lukens T W, Wolf S J, Edlow J A American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department.  Ann Emerg Med. 2006;  47(1) 79-99
• 64 Zuidema S U, van Lersel M B, Koopmans R T, Verhey F R, Olde Rikkert M G. Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review.  Ned Tijdschr Geneeskd. 2006;  150 1565-1573
• 65 Miyaji S, Yamamoto K, Hoshino S, Yamamoto H, Sakai Y, Miyaoka H. Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients.  Psychiatry Clin Neurosci. 2007;  61(3) 275-282
• 66 Riker R R, Fraser G L, Cox P M. Continuous infusion of haloperidol controls agitation in critically ill patients.  Crit Care Med. 1994;  22(3) 433-440
• 67 Fernandez F, Holmes V F, Adams F, Kavanaugh J J. Treatment of severe, refractory agitation with a haloperidol drip.  J Clin Psychiatry. 1988;  49(6) 239-241
• 68 Hassaballa H A, Balk R A. Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use.  Expert Opin Drug Saf. 2003;  2(6) 543-547
• 69 Tisdale J E, Rasty S, Padhi I D, Sharma N D, Rosman H. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes.  J Clin Pharmacol. 2001;  41(12) 1310-1318
• 70 Schneider L S, Dagerman K S, Insel P S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.  Am J Geriatr Psychiatry. 2006;  14(3) 191-210
• 71 Schneider L S, Tariot P N, Dagerman K S CATIE-AD Study Group et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.  N Engl J Med. 2006;  355(15) 1525-1538
• 72 Sultzer D L, Davis S M, Tariot P N CATIE-AD Study Group et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.  Am J Psychiatry. 2008;  165(7) 844-854
• 73 Selbaek G, Kirkevold Ø, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes—a 12-month follow-up study.  Am J Geriatr Psychiatry. 2008;  16(7) 528-536
• 74 Lavretsky H. Neuropsychiatric symptoms in Alzheimer disease and related disorders: why do treatments work in clinical practice but not in the randomized trials?.  Am J Geriatr Psychiatry. 2008;  16(7) 523-527
• 75 Pollock B G, Mulsant B H, Rosen J et al.. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.  Am J Geriatr Psychiatry. 2007;  15(11) 942-952
• 76 Dubovsky S L, Thomas M. Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction.  J Psychosom Res. 1995;  39(4) 429-444
• 77 Cantillon M, Brunswick R, Molina D, Bahro M. Buspirone vs haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease.  Am J Geriatr Psychiatry. 1996;  4 263-267
• 78 Brooke M M, Patterson D R, Questad K A, Cardenas D, Farrel-Roberts L. The treatment of agitation during initial hospitalization after traumatic brain injury.  Arch Phys Med Rehabil. 1992;  73(10) 917-921
• 79 Weiler P G, Mungas D, Bernick C. Propranolol for the control of disruptive behavior in senile dementia.  J Geriatr Psychiatry Neurol. 1988;  1(4) 226-230
• 80 Bearden C E, Thompson P M, Dalwani M et al.. Greater cortical gray matter density in lithium-treated patients with bipolar disorder.  Biol Psychiatry. 2007;  62(1) 7-16
• 81 Ramasubbu R, Kennedy S H. Factors complicating the diagnosis of depression in cerebrovascular disease, Part II—neurological deficits and various assessment methods.  Can J Psychiatry. 1994;  39(10) 601-607
• 82 Ross E D. The aprosodias. Functional-anatomic organization of the affective components of language in the right hemisphere.  Arch Neurol. 1981;  38(9) 561-569
• 83 Van Someren E JW, Kessler A, Mirmiran M, Swaab D F. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients.  Biol Psychiatry. 1997;  41(9) 955-963
• 84 Cornélissen G, Halberg F, Burioka N, Perfetto F, Tarquini R, Bakken E E. Do plasma melatonin concentrations decline with age?.  Am J Med. 2000;  109(4) 343-345
• 85 Okuma T, Kishimoto A. A history of investigation on the mood stabilizing effect of carbamazepine in Japan.  Psychiatry Clin Neurosci. 1998;  52(1) 3-12
• 86 Freeman T W, Clothier J L, Pazzaglia P, Lesem M D, Swann A C. A double-blind comparison of valproate and lithium in the treatment of acute mania.  Am J Psychiatry. 1992;  149(1) 108-111
• 87 Allen M H, Hirschfeld R M, Wozniak P J, Baker J D, Bowden C L. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania.  Am J Psychiatry. 2006;  163 272-275
• 88 Conway C R, Chibnall J T, Nelson L A et al.. An open-label trial of adjunctive oxcarbazepine for bipolar disorder.  J Clin Psychopharmacol. 2006;  26(1) 95-97
• 89 Ettinger A B. Psychotropic effects of antiepileptic drugs.  Neurology. 2006;  67(11) 1916-1925
• 90 Calabrese J R, Bowden C L, Sachs G Lamictal 605 Study Group et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.  J Clin Psychiatry. 2003;  64(9) 1013-1024
• 91 Bowden C L, Calabrese J R, Sachs G Lamictal 606 Study Group et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.  Arch Gen Psychiatry. 2003;  60(4) 392-400
• 92 Reimers A, Skogvoll E, Sund J K, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service.  J Clin Psychopharmacol. 2005;  25(4) 342-348
• 93 Pande A C, Davidson J R, Jefferson J W et al.. Treatment of social phobia with gabapentin: a placebo-controlled study.  J Clin Psychopharmacol. 1999;  19(4) 341-348
• 94 Pohl R B, Feltner D E, Fieve R R, Pande A C. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing.  J Clin Psychopharmacol. 2005;  25(2) 151-158
• 95 Feltner D E, Crockatt J G, Dubovsky S J et al.. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.  J Clin Psychopharmacol. 2003;  23(3) 240-249
• 96 Roy Chengappa K N, Schwarzman L K, Hulihan J F, Xiang J, Rosenthal N R. Clinical Affairs Product Support Study-168 Investigators . Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial.  J Clin Psychiatry. 2006;  67(11) 1698-1706
• 97 Kushner S F, Khan A, Lane R, Olson W H. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials.  Bipolar Disord. 2006;  8(1) 15-27
• 98 Vasudev K, Macritchie K, Geddes J R, Watson S, Young A H. Topiramate for acute affective episodes in bipolar disorder.  Cochrane Database Syst Rev. 2006;  (1) CD003384
• 99 Krüger S, Sarkar R, Pietsch R, Hasenclever D, Bräunig P. Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study.  Psychopharmacology (Berl). 2008;  198(2) 297-299
• 100 Post R M, Altshuler L L, Frye M A et al.. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder.  J Clin Psychiatry. 2005;  66(3) 370-374
• 101 Young A H, Geddes J R, Macritchie K, Rao S N, Vasudev A. Tiagabine in the maintenance treatment of bipolar disorders.  Cochrane Database Syst Rev. 2006;  (3) CD005173
• 102 Ghaemi S N, Shirzadi A A, Klugman J, Berv D A, Pardo T B, Filkowski M M. Is adjunctive open-label zonisamide effective for bipolar disorder?.  J Affect Disord. 2008;  105(1-3) 311-314
• 103 Wang P W, Yang Y S, Chandler R A et al.. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study.  J Psychiatr Res. 2008;  42(6) 451-457
• 104 Corrigan M H, Denahan A Q, Wright C E, Ragual R J, Evans D L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.  Depress Anxiety. 2000;  11(2) 58-65
• 105 Lattanzi L, Dell'Osso L, Cassano P et al.. Pramipexole in treatment-resistant depression: a 16-week naturalistic study.  Bipolar Disord. 2002;  4(5) 307-314
• 106 Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H S. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series.  Pharmacopsychiatry. 2001;  34(4) 137-141
• 107 Rush A J, Sackeim H A, Marangell L B et al.. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.  Biol Psychiatry. 2005;  58(5) 355-363
• 108 Rush A J, George M S, Sackeim H A et al.. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.  Biol Psychiatry. 2000;  47(4) 276-286
• 109 Rush A J, Marangell L B, Sackeim H A et al.. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.  Biol Psychiatry. 2005;  58(5) 347-354
• 110 Sackeim H A, Brannan S K, Rush A J, George M S, Marangell L B, Allen J. Durability of antidepressant response to vagus nerve stimulation (VNS).  Int J Neuropsychopharmacol. 2007;  10(6) 817-826
• 111 Lozano A M, Mayberg H S, Giacobbe P, Hamani C, Craddock R C, Kennedy S H. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression.  Biol Psychiatry. 2008;  64(6) 461-467
• 112 Mallet L, Polosan M, Jaafari N et al.. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder.  N Engl J Med. 2008;  359 2121-2134